FIELD: medicine.
SUBSTANCE: treatment or prevention of osteoporosis is ensured by introduction of a pharmaceutical composition containing approximately 150 mg of bisphosphonic acid. Treatment is administered once a month within one day. As bisphosphonic acid, risedronic acid is used preferentially.
EFFECT: invention allows improving clinical effectiveness and preventing by-effects in comparison with more frequent introduction of bisphosphononates.
6 cl, 1 tbl, 1 ex
Authors
Dates
2010-04-27—Published
2003-05-02—Filed